Prognostic Variables in Low and High Risk Stage III Colon Cancers Treated in Two Adjuvant Chemotherapy Trials
- Citation:
- Eur J Cancer vol 144 101-112
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 10
- Parents:
- 3083
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- GI
- Pharmas:
- Bristol Meyers Squibb, Pfizer, and Sanofi.
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA232760, R01 CA210509-01A1
- Corr. Author:
- Authors:
- Frank A. Sinicrope Sakti Chakrabarti Pierre Laurent-Puig Luke Huebner Thomas C. Smyrk Josep Tabernero Enrico Mini Richard M. Goldberg Aziz Zaanan Gunnar Folprecht Jean Luc Van Laethem Karine Le Malicot Qian Shi Steven R. Alberts Julien Taieb
- Networks:
- LAPS-MN026, LAPS-OH007, LAPS-WI013
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Colon cancer, stage III, adjuvant therapy, risk groups, microsatellite instability, deficient mismatch repair, prognosis, recurrence